Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins
Tumor targeting is a booming business: The global therapeutic monoclonal antibody market accounted for more than $78 billion in 2012 and is expanding exponentially. Tumors can be targeted with an extensive arsenal of monoclonal antibodies, ligand proteins, peptides, RNAs, and small molecules. In add...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Libertas Academica
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040425/ |
| id |
pubmed-5040425 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-50404252016-10-07 Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins Boonstra, Martin C. de Geus, Susanna W.L. Prevoo, Hendrica A.J.M. Hawinkels, Lukas J.A.C. van de Velde, Cornelis J.H. Kuppen, Peter J.K. Vahrmeijer, Alexander L. Sier, Cornelis F.M. Review Tumor targeting is a booming business: The global therapeutic monoclonal antibody market accounted for more than $78 billion in 2012 and is expanding exponentially. Tumors can be targeted with an extensive arsenal of monoclonal antibodies, ligand proteins, peptides, RNAs, and small molecules. In addition to therapeutic targeting, some of these compounds can also be applied for tumor visualization before or during surgery, after conjugation with radionuclides and/or near-infrared fluorescent dyes. The majority of these tumor-targeting compounds are directed against cell membrane-bound proteins. Various categories of targetable membrane-bound proteins, such as anchoring proteins, receptors, enzymes, and transporter proteins, exist. The functions and biological characteristics of these proteins determine their location and distribution on the cell membrane, making them more, or less, accessible, and therefore, it is important to understand these features. In this review, we evaluate the characteristics of cancer-associated membrane proteins and discuss their overall usability for cancer targeting, especially focusing on imaging applications. Libertas Academica 2016-09-27 /pmc/articles/PMC5040425/ /pubmed/27721658 http://dx.doi.org/10.4137/BIC.S38542 Text en © 2016 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article published under the Creative Commons CC-BY-NC 3.0 license. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Boonstra, Martin C. de Geus, Susanna W.L. Prevoo, Hendrica A.J.M. Hawinkels, Lukas J.A.C. van de Velde, Cornelis J.H. Kuppen, Peter J.K. Vahrmeijer, Alexander L. Sier, Cornelis F.M. |
| spellingShingle |
Boonstra, Martin C. de Geus, Susanna W.L. Prevoo, Hendrica A.J.M. Hawinkels, Lukas J.A.C. van de Velde, Cornelis J.H. Kuppen, Peter J.K. Vahrmeijer, Alexander L. Sier, Cornelis F.M. Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins |
| author_facet |
Boonstra, Martin C. de Geus, Susanna W.L. Prevoo, Hendrica A.J.M. Hawinkels, Lukas J.A.C. van de Velde, Cornelis J.H. Kuppen, Peter J.K. Vahrmeijer, Alexander L. Sier, Cornelis F.M. |
| author_sort |
Boonstra, Martin C. |
| title |
Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins |
| title_short |
Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins |
| title_full |
Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins |
| title_fullStr |
Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins |
| title_full_unstemmed |
Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins |
| title_sort |
selecting targets for tumor imaging: an overview of cancer-associated membrane proteins |
| description |
Tumor targeting is a booming business: The global therapeutic monoclonal antibody market accounted for more than $78 billion in 2012 and is expanding exponentially. Tumors can be targeted with an extensive arsenal of monoclonal antibodies, ligand proteins, peptides, RNAs, and small molecules. In addition to therapeutic targeting, some of these compounds can also be applied for tumor visualization before or during surgery, after conjugation with radionuclides and/or near-infrared fluorescent dyes. The majority of these tumor-targeting compounds are directed against cell membrane-bound proteins. Various categories of targetable membrane-bound proteins, such as anchoring proteins, receptors, enzymes, and transporter proteins, exist. The functions and biological characteristics of these proteins determine their location and distribution on the cell membrane, making them more, or less, accessible, and therefore, it is important to understand these features. In this review, we evaluate the characteristics of cancer-associated membrane proteins and discuss their overall usability for cancer targeting, especially focusing on imaging applications. |
| publisher |
Libertas Academica |
| publishDate |
2016 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040425/ |
| _version_ |
1613664205676740608 |